Full-stack commercial support for life sciences and med-tech in the Middle East.

In orthopaedic surgery, instrument availability and precision directly shape clinical outcomes. Yet the very assets that make surgery possible, surgical instrument sets, often sit idle, misplaced, or underused, quietly eroding margin in a cost-sensitive environment.

Shaonie Maitrra led a value-optimisation initiative to address this. Through detailed usage-pattern analysis and inventory rationalisation, she introduced measures that reduced depreciation losses, reclaimed hidden value from the existing asset base, and strengthened revenue realisation. The initiative reshaped how the organisation thought about its supply chain, from a source of operational drag into a lever for margin improvement.

When COVID-era restrictions closed the door on traditional clinical engagement, launching a new med-tech product looked commercially impossible. Sales teams could not visit hospitals. Healthcare professionals could not attend demonstrations. Product education stalled across the market.

Shaonie designed and led a fully virtual "phygital" launch strategy that reopened the channel. Immersive 3D product demonstrations replaced in-person walkthroughs. Physical sample kits were dispatched to clinicians for hands-on evaluation between virtual sessions. Sales engagement was choreographed as a coordinated sequence rather than a series of disconnected touchpoints. The result was a launch that generated adoption and share gains at a moment when most of the category had paused.

In age-sensitive and alternative-medicine-leaning segments, patients often delay diagnosis until conditions become harder to treat. This is not a communication gap, it is a behavioural one. Solving it requires clinical storytelling that meets patients where their hesitations actually live.

Shaonie built a patient-facing campaign framework that combined behavioural insight with clinical narrative. Digital touchpoints seeded early awareness. In-clinic activations reinforced the message at the point of care. Together, the two channels reduced diagnostic delay, moved patients into earlier treatment initiation, and critically did so while strengthening the brand's clinical credibility rather than diluting it into consumer marketing.

Key Opinion Leaders shape adoption in every clinical category, but treating them as a single audience wastes both their time and the brand's investment. An established authority does not need the same content as a rising specialist. A newly identified voice does not respond to the same cadence as a veteran advisor.

Shaonie pioneered a segmentation-led drip marketing strategy that tiered KOLs by influence, (established, rising, and new) and designed distinct engagement flows for each. Educational content was matched to the career stage. Touchpoint frequency was calibrated to relationship depth. Sales enablement was integrated so field teams knew where each conversation stood. The result was deeper clinician relationships built through relevance, not repetition.

In healthcare markets crowded with lookalike products, premium positioning cannot rest on clinical features alone. Buyers including hospitals, payers, and health systems need a defensible economic case that stands up to scrutiny long after the sales conversation ends.

Contributing to a cross-functional market access initiative, Shaonie helped frame that case. The work drew on established healthcare economic metrics including Average Length of Stay, Quality-Adjusted Life Years, cost-per-outcome to show that superior clinical performance translated into system-wide savings. The narrative moved the product from a feature-led pitch to a value-led argument. That shift changed how procurement teams evaluated the category and how clinicians defended the choice internally.